Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Adenocarcinoma of Lung 2Mesothelioma, Malignant 1Lymphoma 1Lung Neoplasms 1Colonic Neoplasms 1

Interventions

Carboplatin 41Cisplatin 38Paclitaxel 34Specimen Handling 32Radiotherapy 27Magnetic Resonance Spectroscopy 25Gemcitabine 23Vinorelbine 15Etoposide 15Docetaxel 15Biopsy 13Pemetrexed 10Cyclophosphamide 10pembrolizumab 9Taxes 9Immunoglobulin G 9Disulfides 9Platinum 81,2-diaminocyclohexaneplatinum II citrate 8X-Rays 7Vinblastine 7Erlotinib Hydrochloride 7osimertinib 6durvalumab 6atezolizumab 6Nivolumab 6Irinotecan 6Ifosfamide 6Chemotherapy, Adjuvant 6Celecoxib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lung Neoplasms × methoxyamine × Clear all
NCT05198830 2026-05-27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
42 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡